Xeris Pharmaceuticals Inc (NASDAQ:XERS) — Market Cap & Net Worth
Market Cap & Net Worth: Xeris Pharmaceuticals Inc (XERS)
Xeris Pharmaceuticals Inc (NASDAQ:XERS) has a market capitalization of $1.39 Billion ($1.39 Billion) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7394 globally and #2236 in its home market, demonstrating a -3.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xeris Pharmaceuticals Inc's stock price $8.08 by its total outstanding shares 172642055 (172.64 Million). See capital reinvestment ratio of Xeris Pharmaceuticals Inc to understand how much of operating cash flow is reinvested back into capital assets.
Xeris Pharmaceuticals Inc Market Cap History: 2018 to 2026
Xeris Pharmaceuticals Inc's market capitalization history from 2018 to 2026. Data shows change from $2.93 Billion to $1.39 Billion (-10.69% CAGR).
Index Memberships
Xeris Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.06% | #213 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #823 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.08% | #129 of 263 |
Weight: Xeris Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Xeris Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xeris Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.64x
Xeris Pharmaceuticals Inc's market cap is 4.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2446.28x
Xeris Pharmaceuticals Inc's market cap is 2446.28 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $2.93 Billion | $2.46 Million | -$60.08 Million | 1190.63x | N/A |
| 2019 | $1.22 Billion | $2.72 Million | -$125.58 Million | 447.14x | N/A |
| 2020 | $849.40 Million | $2.72 Million | -$125.58 Million | 312.05x | N/A |
| 2021 | $505.84 Million | $49.59 Million | -$122.72 Million | 10.20x | N/A |
| 2022 | $229.61 Million | $110.25 Million | -$94.66 Million | 2.08x | N/A |
| 2023 | $405.71 Million | $163.91 Million | -$62.26 Million | 2.48x | N/A |
| 2024 | $585.26 Million | $203.07 Million | -$54.84 Million | 2.88x | N/A |
| 2025 | $1.36 Billion | $291.85 Million | $554.00K | 4.64x | 2446.28x |
Competitor Companies of XERS by Market Capitalization
Companies near Xeris Pharmaceuticals Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Xeris Pharmaceuticals Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #503 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #528 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.48 Billion | CN¥54.08 |
| #550 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.60 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.80 |
Xeris Pharmaceuticals Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Xeris Pharmaceuticals Inc's market cap moved from $2.93 Billion to $ 1.39 Billion, with a yearly change of -10.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.39 Billion | +2.93% |
| 2025 | $1.36 Billion | +131.56% |
| 2024 | $585.26 Million | +44.26% |
| 2023 | $405.71 Million | +76.69% |
| 2022 | $229.61 Million | -54.61% |
| 2021 | $505.84 Million | -40.45% |
| 2020 | $849.40 Million | -30.21% |
| 2019 | $1.22 Billion | -58.53% |
| 2018 | $2.93 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Xeris Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.39 Billion USD |
| MoneyControl | $1.39 Billion USD |
| MarketWatch | $1.39 Billion USD |
| marketcap.company | $1.39 Billion USD |
| Reuters | $1.39 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xeris Pharmaceuticals Inc
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related … Read more